Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / TLT:CC - Theralase Technologies shares positive interim results from Phase II Bladder Cancer study

TLT:CC - Theralase Technologies shares positive interim results from Phase II Bladder Cancer study

Theralase Technologies Inc.

--News Direct--

Theralase Technologies CEO Roger DuMoulin-White joined Steve Darling from Proactive to share interim data from a Phase II clinical study designed to treat patients diagnosed with Bacillus Calmette-Guérin Unresponsive, Non-Muscle Invasive Bladder Cancer and Carcinoma In-Situ with a patented investigational study drug Ruvidar, subsequently activated by a proprietary investigational study laser system equipped with fiber-optic light emitters and detectors.

DuMoulin-White discussed more about the study and what the interim data is telling them about the study.

He also talked about the company and the other vertical it has with its Cool Laser Therapy which is focused on the research, development, production and distribution of medical laser technologies for healing pain.

Contact Details

Proactive Investors

+1 604-688-8158

na-editorial@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/theralase-technologies-shares-positive-interim-results-from-phase-ii-bladder-cancer-study-682839572

Stock Information
Company Name: Theralase Technologies Inc.
Stock Symbol: TLT:CC
Market: TSXVC
Website: theralase.com
Menu
TLT:CC TLT:CC Quote TLT:CC Short TLT:CC News TLT:CC Articles TLT:CC Message Board
Get TLT:CC Alerts

News, Short Squeeze, Breakout and More Instantly...